Elli Papaemmanuil, Co-Founder and CEO of Isabl and Associate Professor of Computational Oncology Service at MSKCC, shared a post on X by Eric Topol, Founder and Director of the Scripps Research Translational Institute, about a paper she co-authored with colleagues published in NEJM:
“Tumor-Infiltrating Clonal Hematopoiesis”
Authors: Oriol Pich, Elsa Bernard, Maria Zagorulya, Andrew Rowan, Constandina Pospori, Charles Rudin, Adam Mead, Dominique Bonnet, Elli Papaemmanuil, Charles Swanton et al.
“It has been unclear why cancer patients with CH have worse outcomes. Our work published in NEJM uncovers that Tumour-infiltrating CH (TI-CH) has a direct role in immune remodelling of the TME with implications for tumor progression and treatment response.”
Quoting Eric Topol’s post:
“New evidence today in NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers.”
More posts featuring Eric Topol.